hotspot -WSS

hotspot

author：comprehensive 2025-10-01 09:00:17 - browse：2

Duchenne muscular dystrophy is a devastating disease and, until very recently, was one without much hope. When Hawken Miller was diagnosed at age 5, the physician told his parents to enjoy the time they had with him, as there wouldn’t be much. Over 20 years later, Miller is a journalist and content strategist for CureDuchenne, an organization started by his mother when he was diagnosed, and new treatment is on the horizon.

Last month, the FDA approved a new gene therapy from Sarepta Therapeutics that will provide hope for many patients and families. The new drug, however, has its limitations — it’s only approved for children age 4-5, for example. Miller joined the podcast to discuss how this drug may change lives, what more needs to happen, and what his personal experience has been living with Duchenne.

“For the older boys, we’re running up against the clock a little bit with what we’re able to do and what we’re not able to do,” Miller said. “And if we’re able to try anything that could possibly help, I think most people would like the opportunity to do that.”

The conversation is based off his recent First Opinion, “The FDA’s approval of a new gene therapy for Duchenne muscular dystrophy won’t help me — but it gives me hope.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： 2023 STAT Wunderkinds: get to know the winners

WSS

CEOs share strategies for surviving biotech slump

Anesthesiologist group: stop taking Ozempic before surgery

FDA struggles to regulate food additives, sometimes for decades

In Memoriam: Notable people who died in 2023

Pharmacists can make shortage drugs, but at what cost?

Solve the antibiotic resistance crisis with preventive drugs

focus

hotspot

hotspot

Apple is now the first public company to be valued at $3 trillion

CEOs share strategies for surviving biotech slump

BioMarin wins approval for gene therapy to treat hemophilia A

Pharmacists can make shortage drugs, but at what cost?

At least 13 dead in Texas as scorching temps continue

2023 STAT Wunderkinds: get to know the winners

Supreme Court strikes down use of affirmative action

Drug repurposing or repositioning? The language matters

How to save PrEP access — and even expand it

Researchers explore possible ties between long Covid, menopause

focus

STAT Readout Newsletter: Today's biggest biotech updates

Novavax promises a turnaround & Lilly roils the obesity market

NIH confirmation hearing shows politicization of research

Medicare proposal to cover medical devices draws a mixed reaction

BioMarin wins approval for gene therapy to treat hemophilia A

In age of alternative facts, a scholarly course on calling out crap

Wikipedia

focus

hotspot

explore